Nerites Receives NIH Grant to Study Novel Treatment for Preventing Dangerous Bacterial Infections on Urinary Stents and Catheters
Posted on: Monday, 21 January 2008, 09:01 CST
MADISON, Wis., Jan. 21 /PRNewswire/ -- While urinary stents and catheters can be life-saving medical devices, 40 percent of patients end up with bacterial infections. With 100 million placed in patients each year, this means that doctors must treat 40 million device-associated infections annually. Nerites Corporation is testing its unique new technology for preventing these dangerous infections, with funding from a $100,000 small business innovation research grant (SBIR) from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institutes of Health (NIH).
The study will determine whether Nerites novel polymer coatings can prevent biofilm growth, the source of most infections on urinary stents and catheters. Biofilms grow on the surface of the device and provide an anchor for bacteria, which then recruit other bacteria and cause infection.
"Current methods to prevent biofilms are expensive, often ineffective and can promote antibiotic resistance," said Thomas J. Mozer, Ph.D., CEO and President of Nerites Corporation. "This money will help us test our coating technology, which we believe will block biofilm formation reliably and inexpensively, without antibiotics or biocides."
About Nerites: Nerites Corporation develops novel tissue repair products as well as advanced coatings for implanted medical devices and device uses on skin based on unique "wet" adhesive compounds. These synthetic compounds are based upon research by Dr. Phil Messersmith at Northwestern University's Department of Biomedical Engineering on how marine mussels bind to surfaces underwater, are a breakthrough advance in biologically-compatible adhesives that provide completely new options for tissue repair, skin adhesives, and device coatings. Nerites is based in Madison Wisconsin. (http://www.nerites.com/)
Nerites Corporation
CONTACT: Thomas J. Mozer, Ph.D., CEO-President Nerites Corporation,+1-608-443-2440, tmozer@nerites.com
Web site: http://www.nerites.com/
Source: PRNewswire
Related Articles
- Leading Physicians To Host Medical Device Related Infection Prevention CME Webcast
- CeraShield(TM) Coated Endotracheal Tubes Provide Up to 21 Days of Protection Against Bacterial Colonization in Preclinical Testing
- CellTraffix Implanted Device Captures Stem Cells From Blood Stream in Live Rats
- TyRx Pharma, Inc. Announces Food and Drug Administration (FDA) 510(K) Clearance of the AIGIS(Rx)(TM) Cardiac Rhythm Medical Device (CRMD) Anti-Bacterial Envelope, an Innovative Mesh Envelope Designed to Immobilize and Reduce Bacterial Infection of a Pacem
- Ceragenix Pharmaceuticals Receives Frost & Sullivan Product Innovation Award for Cerashield(TM) Coating
- CardioTech Announces Patent Filing for Antimicrobial Polymers Designed to Avoid Infections Without Using Antibiotic Drugs
- Valspar Reports Fourth Quarter and Full Year Results
- Biophan Licensor Issued Broad Patent on Nanomagnetic Coatings; Licensing Negotiations Continue
- MultiCell's Xenogenics Subsidiary Granted Artificial Liver Device Patent; Sybiol Device Offers Potential To Treat Millions of Patients With Liver Trauma or Insufficiency
 |
 |
User Comments (0)
RSS Feeds